Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Entyvio (Vedolizumab) Clear all
Not yet recruiting No phase listed Observational

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

NCT07250815
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
23,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Recruiting No phase listed Observational

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

NCT04372108
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
Ustekinumab, Other Biologic Therapies
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT03196427
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Completed No phase listed Observational

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308
View directory record Official record
Conditions
Ulcerative Colitis and Crohn's Disease
Interventions
Vedolizumab, Other Biologic Agents
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 28, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961308
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 28, 2026, 6:46 PM EDT
Active, not recruiting No phase listed Observational

Response Assessment in SB CD

NCT03646708
View directory record Official record
Conditions
Small Bowel Crohn's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Recruiting Phase 3 Interventional

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06405087
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab SC, No Intervention
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

NCT02497469
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 28, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

NCT03760003
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
San Diego, California • Decatur, Georgia • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 28, 2026, 6:46 PM EDT
Recruiting No phase listed Observational

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

NCT07198113
View directory record Official record
Conditions
Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 18 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 28, 2026, 6:46 PM EDT
Completed No phase listed Observational

Cytokines and Genes in Therapeutic Response in Crohn's Disease

NCT03266471
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Baseline blood sample, Baseline intestinal biopsies, Crohn's disease activity index (CDAI), Post treatment blood sample, Post treatment intestinal biopsies, Baseline stool sample, Post treatment stool sample
Diagnostic Test · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 28, 2026, 6:46 PM EDT
Active, not recruiting Phase 2 Interventional

Vedolizumab for the Treatment of Collagenous Gastritis

NCT06317220
View directory record Official record
Conditions
Collagenous Gastritis
Interventions
Vedolizumab
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Recruiting Phase 4 Interventional

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

NCT06257706
View directory record Official record
Conditions
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
Interventions
Vedolizumab
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis

NCT02790138
View directory record Official record
Conditions
Pouchitis
Interventions
Vedolizumab Placebo, Ciprofloxacin, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 28, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT03138655
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 28, 2026, 6:46 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Vedolizumab Induction May Prevent Celiac Enteritis

NCT02929316
View directory record Official record
Conditions
Celiac Disease
Interventions
Vedolizumab
Drug
Lead sponsor
AGA Clinical Research Associates, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Egg Harbor, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 28, 2026, 6:46 PM EDT
Withdrawn Phase 2 Interventional

Vedolizumab Post Op Study

NCT02834754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, placebo
Drug
Lead sponsor
Marc Schwartz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 28, 2026, 6:46 PM EDT
Withdrawn Phase 4 Interventional

An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis

NCT03237260
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vedolizumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 28, 2026, 6:46 PM EDT
Completed Phase 4 Interventional Results available

Defining Predictors of RT Response to Vedolizumab in IBD

NCT03142321
View directory record Official record
Conditions
Crohn Disease of Small Intestine
Interventions
Vedolizumab 300 MG Injection [Entyvio]
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 28, 2026, 6:46 PM EDT
Active, not recruiting No phase listed Observational

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA), Guselkumab (GUS), Mirikizumab (MIR)
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 28, 2026, 6:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

OTIS Vedolizumab Pregnancy Exposure Registry

NCT02678052
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab, Other Biological Agent
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 28, 2026, 6:46 PM EDT
Terminated Phase 4 Interventional Results available

Corticosteroids With Vedolizumab in Crohn's Disease

NCT02324699
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prednisone, Placebo, Vedolizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 28, 2026, 6:46 PM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, No Intervention
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 28, 2026, 6:46 PM EDT